Phaseline

Targets › VEGFR2

VEGFR2 (Vascular endothelial growth factor receptor 2): drug programs, companies and trials

5 programs from 5 companies in 11 trials: 4 Phase 2, 4 Phase 1, 3 Phase 3; Oncology, Ophthalmology; next expected readout Dec 2026.

Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. (UniProt, P35968)

Open in Phaseline: the race on VEGFR2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
4D Molecular Therapeutics4D-150
AAV-based gene therapy delivering miRNA targeting VEGF-C and codon-optimized aflibercept s
VEGFA, VEGFC, VEGFR2Phase 3Macular Neovascularization Secondary to Age-Related Macular Degeneration; Neovascular Age-Related Macular Degeneration (nAMD); Diabetic Macular Edema (DME); Diabetic Macular Edema …Mar 2027
Beijing Scitech-Mq PharmaceuticalsST-1898
Receptor tyrosine kinase (RTK) inhibitor targeting VEGFR2, c-MET, AXL, PDGFRA, RET, and KI
VEGFR2, MET, AXL, PDGFRA, RETPhase 2Differentiated Thyroid Carcinoma; Unresectable or Metastatic Melanoma; Advanced Renal Cell CarcinomaDec 2026
Fei GaoDonafenib
Multi-kinase inhibitor targeting FGFR and VEGFR
FGFR1, VEGFR1, VEGFR2, VEGFR3Phase 2Hepatocellular Carcinoma with PVTTDec 2026
Karie RuncieZanzalintinib (XL092)
Multi-targeted receptor tyrosine kinase inhibitor targeting VEGF receptors
VEGFR1, VEGFR2, VEGFR3Phase 2Advanced Renal Cell CarcinomaDec 2027
Etnova TherapeuticsETN101
Multiple tyrosine kinase inhibitor targeting FLT3, KIT, VEGFR2, and PDGFRB
FLT3, KIT, VEGFR2, PDGFRBPhase 1Hepatocellular CarcinomaMar 2027

Conditions

Advanced Renal Cell Carcinoma (2) Differentiated Thyroid Carcinoma (1) Unresectable or Metastatic Melanoma (1) Macular Neovascularization Secondary to Age-Related Macular Degeneration (1) Neovascular Age-Related Macular Degeneration (nAMD) (1) Diabetic Macular Edema (DME) (1) Diabetic Macular Edema (1) Neovascular (Wet) Age-Related Macular Degeneration (1) Hepatocellular Carcinoma (1) Hepatocellular Carcinoma with PVTT (1)

Modalities

small molecule (3), mixed (2)

Companies

Beijing Scitech-Mq Pharmaceuticals (1) Karie Runcie (1) 4D Molecular Therapeutics (1) Etnova Therapeutics (1) Fei Gao (1)

Related targets

VEGFR1 (2) VEGFR3 (2) MET (1) AXL (1) PDGFRA (1) RET (1) VEGFA (1) VEGFC (1) FLT3 (1) KIT (1) PDGFRB (1) FGFR1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.